Oppenheimer Weighs in on Kura Oncology Inc’s FY2020 Earnings (KURA)

Kura Oncology Inc (NASDAQ:KURA) – Stock analysts at Oppenheimer reduced their FY2020 earnings estimates for Kura Oncology in a research report issued on Monday, November 5th. Oppenheimer analyst L. Cann now forecasts that the company will post earnings per share of $4.40 for the year, down from their previous forecast of $4.75. Oppenheimer also issued estimates for Kura Oncology’s FY2021 earnings at $7.67 EPS.

KURA has been the subject of a number of other research reports. Zacks Investment Research raised shares of Kura Oncology from a “sell” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Tuesday, October 16th. Cann initiated coverage on shares of Kura Oncology in a research note on Monday. They set a “buy” rating and a $35.00 target price for the company. BidaskClub raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. HC Wainwright set a $31.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research note on Thursday, November 1st. Finally, ValuEngine raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $27.67.

Shares of NASDAQ KURA opened at $11.91 on Wednesday. Kura Oncology has a fifty-two week low of $10.20 and a fifty-two week high of $24.02. The company has a market cap of $439.09 million, a price-to-earnings ratio of -7.84 and a beta of 4.39. The company has a quick ratio of 10.22, a current ratio of 14.76 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Monday, November 5th. The company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.01.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC increased its position in shares of Kura Oncology by 0.5% during the second quarter. Millennium Management LLC now owns 524,872 shares of the company’s stock valued at $9,553,000 after acquiring an additional 2,661 shares in the last quarter. Barclays PLC increased its position in shares of Kura Oncology by 67.0% during the first quarter. Barclays PLC now owns 8,977 shares of the company’s stock valued at $168,000 after acquiring an additional 3,600 shares in the last quarter. Rhumbline Advisers increased its position in shares of Kura Oncology by 30.7% during the second quarter. Rhumbline Advisers now owns 23,647 shares of the company’s stock valued at $430,000 after acquiring an additional 5,552 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Kura Oncology by 35.1% during the third quarter. Alliancebernstein L.P. now owns 22,700 shares of the company’s stock valued at $397,000 after acquiring an additional 5,900 shares in the last quarter. Finally, Alps Advisors Inc. increased its position in shares of Kura Oncology by 19.4% during the second quarter. Alps Advisors Inc. now owns 48,400 shares of the company’s stock valued at $881,000 after acquiring an additional 7,874 shares in the last quarter. 77.28% of the stock is owned by institutional investors.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Featured Story: Return on Investment (ROI) Defined, Explained

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply